Tagged with OTC

Turkey Barış Özyurtlu, general manager of Berko Pharmaceuticals, one of the fastest growing companies in Turkey, provides insights into the company’s innovative vision and proprietary technologies, such as its spoon-shaped product presentation. The latter has already caught the attention of several partners in the US and Canada and should further propel…

Turkey Kazim Dinç, chairman of the board of SURDER and former Minister of Health of Turkey, offers his insights into the Turkish OTC and health products market, highlighting the challenges facing the industry and SURDER’s role in bringing about constructive reforms.   Before SURDER was established, there was a sizeable gap…

Malaysia Smit Soni, Kalbe country manager for Malaysia and Singapore, explains the dynamics in the consumer healthcare market in Malaysia, and how Kalbe is ensuring that its products are being adapted to rising health consciousness and the changing tastes of Malaysian consumers. He also discusses Kalbe’s new move into the oncology…

Spain Oriol Segarra, CEO of Uriach, describes the Spanish OTC company’s recent developments and transformation from a domestic organization to a truly European player.   These are very interesting times for Uriach; the company is celebrating its 180th anniversary, has just won OTC company of the year, and has invested in…

Portugal Experienced country manager, João Madeira, introduces Mylan’s new vision to be a global healthcare company serving patients across the world with their hybrid generic, OTC and innovative pharmaceutical business model which in the same breath sustains and innovates the healthcare system. Touching on themes of talent, biosimilars, and Portugal as…

Spain Jaume Pey, director general at the Spanish Association of Self-care (ANEFP), discusses the growth projections of the self-care segment in Spain, the impact that the ‘supresión del control previo sanitario’ (suppression of prior health control) has had on the advertising campaigns of ANEFP’s members, as well as the importance of…

UK After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back and analyses the new Mylan, while highlighting how it is fit for the future of healthcare. How does Mylan position…

Baltics In terms of being able to access medicines, patients in the Baltic states fare poorly compared to many of their European counterparts. 135 new medicines were approved by regulators in Lithuania and Estonia in 2016, but only 38 and 30 were made available to patients respectively. Latvia fares even worse,…

Poland As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top five generics company in the country by 2021. He also touches on the importance of a high-performing team, the exciting…

UK John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the overall UK economy, and why self-care remains a priority. A year after becoming chief executive of the PAGB, the UK…

Poland Andrzej Schonert, CEO of Synoptis Industrial, discusses the intricacies of the Polish market and the requirement to move into niche areas, mainly in Rx, to concentrate their pharmaceutical offering to pharmacists, and in the future, hospitals. Furthermore, he highlights the company’s CMO activities and services to assist foreign players to…

Poland Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights Polpharma’s digital approach and the company’s long-term vision for sustained success across the region.   Our international markets are growing…